The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice
Open accessAbstract
Diet-induced obesity is associated with fatty liver, insulin resistance, leptin resistance, and changes in plasma lipid profile. Endocannabinoids have been implicated in the development of these associated phenotypes, because mice deficient for the cannabinoid receptor CB1 (CB1-/-) do not display these changes in association with diet-induced obesity. The target tissues that mediate these effects, however, remain unknown. We therefore investigated the relative role of hepatic versus extrahepatic CB1 receptors in the metabolic consequences of a high-fat diet, using liver-specific CB1 knockout (LCB1-/-) mice. LCB1(-/-) mice fed a high-fat diet developed a similar degree of obesity as that of wild-type mice, but, similar to CB1(-/-) mice, had less steatosis, hyperglycemia, dyslipidemia, and insulin and leptin resistance than did wild-type mice fed a high-fat diet. CB1 agonist-induced increase in de novo hepatic lipogenesis and decrease in the activity of carnitine palmitoyltransferase-1 and total energy expenditure were absent in both CB1(-/-) and LCB1(-/-) mice. We conclude that endocannabinoid activation of hepatic CB1 receptors contributes to the diet-induced steatosis and associated hormonal and metabolic changes, but not to the increase in adiposity, observed with high-fat diet feeding. Theses studies suggest that peripheral CB1 receptors could be selectively targeted for the treatment of fatty liver, impaired glucose homeostasis, and dyslipidemia in order to minimize the neuropsychiatric side effects of nonselective CB1 blockade during treatment of obesity-associated conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes
Yang, Q., Graham, T. E., Mody, N., Preitner, F., Peroni, O. D., Zabolotny, J. M., Kotani, K., Quadro, L., & Kahn, B. B. (2005) · Nature · doi:10.1038/nature03711 · Cited by 2,086
Leptin-regulated endocannabinoids are involved in maintaining food intake
Di Marzo, V., Goparaju, S. K., Wang, L., Liu, J., Bátkai, S., Járai, Z., Fezza, F., Miura, G. I., Palmiter, R. D., Sugiura, T., et al. (2001) · Nature · doi:10.1038/35071088 · Cited by 1,559
Self-citationVan Gaal, L. F., Rissanen, A. M., Scheen, A. J., Ziegler, O., & Rössner, S. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66374-x · Cited by 1,499
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392
Postic, C., Shiota, M., Niswender, K. D., Jetton, T. L., Chen, Y., Moates, J. M., Shelton, K. D., Lindner, J., Cherrington, A. D., & Magnuson, M. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.1.305 · Cited by 1,302
Pi-Sunyer, F. X., Aronne, L. J., Heshmati, H. M., Devin, J., Rosenstock, J., & RIO-North America Study Group, F. T. (2006) · JAMA · doi:10.1001/jama.295.7.761 · Cited by 1,218
CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity
Marsicano, G., Goodenough, S., Monory, K., Hermann, H., Eder, M., Cannich, A., Azad, S. C., Cascio, M. G., Gutiérrez, S. O., van der Stelt, M., et al. (2003) · Science · doi:10.1126/science.1088208 · Cited by 1,208
Self-citationCota, D., Marsicano, G., Tschöp, M., Grübler, Y., Flachskamm, C., Schubert, M., Auer, D., Yassouridis, A., Thöne-Reineke, C., Ortmann, S., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17725 · Cited by 1,168
Self-citationOsei-Hyiaman, D., DePetrillo, M., Pacher, P., Liu, J., Radaeva, S., Bátkai, S., Harvey-White, J., Mackie, K., Offertáler, L., Wang, L., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523057 · Cited by 1,101
Self-citationEfficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61721-8 · Cited by 1,097 · cited 1×
“The therapeutic potential of CB1 antagonists in obesity/metabolic syndrome appears to be limited by CNS-mediated side effects, including anxiety and depression (35).”
BackgroundIncreased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice
Zimmer, A., Zimmer, A. M., Hohmann, A. G., Herkenham, M., & Bonner, T. I. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5780 · Cited by 1,064
Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity
El-Haschimi, K., Pierroz, D. D., Hileman, S. M., Bjørbæk, C., & Flier, J. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9842 · Cited by 887
The Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy Balance
Pagotto, U., Marsicano, G., Cota, D., Lutz, B., & Pasquali, R. (2006) · Endocrine Reviews · doi:10.1210/er.2005-0009 · Cited by 865
Self-citationShimano, H., Horton, J. D., Hammer, R. E., Shimomura, I., Brown, M. S., & Goldstein, J. L. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118951 · Cited by 816
Bensaid, M., Gary-Bobo, M., Esclangon, A., Maffrand, J. P., Le Fur, G., Oury-Donat, F., & Soubrié, P. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.4.908 · Cited by 593
Ravinet Trillou, C., Delgorge, C., Menet, C., Arnone, M., & Soubrié, P. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802583 · Cited by 583
Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice
Ravinet Trillou, C., Arnone, M., Delgorge, C., Gonalons, N., Keane, P., Maffrand, J.-P., & Soubrié, P. (2003) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00545.2002 · Cited by 566
Kudo, N., Barr, A. J., Barr, R. L., Desai, S., & Lopaschuk, G. D. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.29.17513 · Cited by 564
Overfeeding Rapidly Induces Leptin and Insulin Resistance
Wang, J., Obici, S., Morgan, K., Barzilai, N., Feng, Z., & Rossetti, L. (2001) · Diabetes · doi:10.2337/diabetes.50.12.2786 · Cited by 355
Liu, Y. L., Connoley, I. P., Wilson, C. A., & Stock, M. J. (2005) · International Journal of Obesity · doi:10.1038/sj.ijo.0802847 · Cited by 313
Jeong, W.-I., Osei-Hyiaman, D., Park, O., Liu, J., Bátkai, S., Mukhopadhyay, P., Horiguchi, N., Harvey-White, J., Marsicano, G., Lutz, B., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.12.007 · Cited by 310
Self-citationGary-Bobo, M., Elachouri, G., Gallas, J. F., Janiak, P., Marini, P., Ravinet-Trillou, C., Chabbert, M., Cruccioli, N., Pfersdorff, C., Roque, C., et al. (2007) · Hepatology · doi:10.1002/hep.21641 · Cited by 304
Apolipoprotein C-III: understanding an emerging cardiovascular risk factor
Ooi, E. M. M., Barrett, P. H. R., Chan, D. C., & Watts, G. F. (2008) · Clinical Science · doi:10.1042/cs20070308 · Cited by 282 · cited 1×
“Chronic, heavy marijuana use has also been recently found to increase the plasma level of apolipoprotein C-III (22), a liver-derived plasma constituent that correlates with dyslipidemia and cardiovascular risk in the metabolic syndrome (23).”
BackgroundNeuronal Pathway from the Liver Modulates Energy Expenditure and Systemic Insulin Sensitivity
Uno, K., Katagiri, H., Yamada, T., Ishigaki, Y., Ogihara, T., Imai, J., Hasegawa, Y., Gao, J., Kaneko, K., Iwasaki, H., et al. (2006) · Science · doi:10.1126/science.1126010 · Cited by 262
Integration of Endocannabinoid and Leptin Signaling in an Appetite-Related Neural Circuit
Jo, Y.-H., Chen, Y.-J. J., Chua, S. C., Talmage, D. A., & Role, L. W. (2005) · Neuron · doi:10.1016/j.neuron.2005.10.021 · Cited by 234
Critical role of STAT3 in leptin's metabolic actions
Buettner, C., Pocai, A., Muse, E. D., Etgen, A. M., Myers, M. G., & Rossetti, L. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.04.014 · Cited by 228 · cited 1×
“For example, centrally acting leptin was previously shown to affect hepatic glucose fluxes (15) and hepatic lipid metabolism (16), possibly through neural input to the liver.”
BackgroundSelf-citationSite and mechanism of leptin action in a rodent form of congenital lipodystrophy
Asilmaz, E., Cohen, P., Miyazaki, M., Dobrzyn, P., Ueki, K., Fayzikhodjaeva, G., Soukas, A. A., Kahn, C. R., Ntambi, J. M., Socci, N. D., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200419511 · Cited by 210
Site and mechanism of leptin action in a rodent form of congenital lipodystrophy
Asilmaz, E., Cohen, P., Miyazaki, M., Dobrzyn, P., Ueki, K., Fayzikhodjaeva, G., Soukas, A. A., Kahn, C. R., Ntambi, J. M., Socci, N. D., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19511 · Cited by 210
The anti‐obesity effect of rimonabant is associated with an improved serum lipid profile
Poirier, B., Bidouard, J. ‐., Cadrouvele, C., Marniquet, X., Staels, B., O'Connor, S. E., Janiak, P., & Herbert, J. ‐. (2005) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00374.x · Cited by 203
Daily Cannabis Use: A Novel Risk Factor of Steatosis Severity in Patients With Chronic Hepatitis C
Hézode, C., Zafrani, E. S., Roudot–Thoraval, F., Costentin, C., Hessami, A., Bouvier–Alias, M., Medkour, F., Pawlostky, J., Lotersztajn, S., & Mallat, A. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.11.039 · Cited by 190
Tedesco, L., Valerio, A., Cervino, C., Cardile, A., Pagano, C., Vettor, R., Pasquali, R., Carruba, M. O., Marsicano, G., Lutz, B., et al. (2008) · Diabetes · doi:10.2337/db07-1623 · Cited by 145
Self-citationSiegmund, S., Qian, T., Minicis, S. D., Harvey-White, J. D., Kunos, G., Vinod, K. Y., Hungund, B. L., & Schwabe, R. F. (2007) · The FASEB Journal · doi:10.1096/fj.06-7717com · Cited by 127
Self-citationActivation of cannabinoid CB1 receptors induces glucose intolerance in rats
Bermúdez‐Silva, F. J., Serrano, A., Diaz-Molina, F. J., Sánchez-Vera, I., Juan-Picó, P., Nadal, Á., Fuentes, E., & de Fonseca, F. R. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.12.016 · Cited by 109
Herling, A. W., Kilp, S., Elvert, R., Haschke, G., & Kramer, W. (2008) · Endocrinology · doi:10.1210/en.2007-1515 · Cited by 108
Serrano, A., del Arco, I., Pavón, F. J., Macías, M., Perez‐Valero, V., & de Fonseca, F. R. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.03.007 · Cited by 79
IL-6 modulates hepatocyte proliferation via induction of HGF/p21cip1: Regulation by SOCS3
Sun, R., Jaruga, B., Kulkarni, S., Sun, H., & Gao, B. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.10.171 · Cited by 73
Doyon, C., Denis, R., Baraboi, E., Samson, P., Lalonde, J., Deshaies, Y., & Richard, D. (2006) · Diabetes · doi:10.2337/db06-0504 · Cited by 73
MCH−/− Mice Are Resistant to Aging-Associated Increases in Body Weight and Insulin Resistance
Jeon, J. Y., Bradley, R. L., Kokkotou, E. G., Marino, F. E., Wang, X., Pissios, P., & Maratos–Flier, E. (2006) · Diabetes · doi:10.2337/diabetes.55.02.06.db05-0203 · Cited by 72
Ji, H. L., & Friedman, M. I. (2007) · Metabolism · doi:10.1016/j.metabol.2007.04.006 · Cited by 61
Herling, A. W., Gossel, M., Haschke, G., Stengelin, S., Kuhlmann, J., Müller, G. A., Schmoll, D., & Kramer, W. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00264.2007 · Cited by 42
Jayanthi, S., Buie, S., Moore, S., Herning, R. I., BETTER, W. E., Wilson, N. M., Contoreggi, C. S., & Cadet, J. L. (2008) · Molecular Psychiatry · doi:10.1038/mp.2008.50 · Cited by 23
High-density lipoprotein cholesterol and residual cardiometabolic risk in metabolic syndrome
Cannon, C. P. (2007) · Clinical cornerstone · doi:10.1016/s1098-3597(07)80011-1 · Cited by 22
Cited by
SREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology
Shimano, H., & Sato, R. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.91 · Cited by 1,174
The endocannabinoid system links gut microbiota to adipogenesis
Muccioli, G. G., Naslain, D., Bäckhed, F., Reigstad, C. S., Lambert, D. M., Delzenne, N. M., & Cani, P. D. (2010) · Molecular Systems Biology · doi:10.1038/msb.2010.46 · Cited by 691
Endocannabinoid signaling at the periphery: 50 years after THC
Maccarrone, M., Bab, I., Bíró, T., Cabral, G. A., Dey, S. K., Di Marzo, V., Konje, J. C., Kunos, G., Mechoulam, R., Pacher, P., et al. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.02.008 · Cited by 646
Self-citationThe gut microbiota, obesity and insulin resistance
Shen, J., Obin, M. S., & Zhao, L. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.11.001 · Cited by 599
The Endocannabinoid System in Energy Homeostasis and the Etiopathology of Metabolic Disorders
Silvestri, C., & Di Marzo, V. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.03.001 · Cited by 543
Metadata
- Authors
- Osei-Hyiaman, D., Liu, J., Zhou, L., Godlewski, G., Harvey-White, J., Jeong, W.-I., Bátkai, S., Marsicano, G., Lutz, B., Buettner, C., & Kunos, G.
- Venue
- Journal of Clinical Investigation
- Published
- 2008-09-02
- Volume
- 118
- Issue
- 9
- Pages
- 3160-3169
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2146709170
- Cited by
- 458
- References
- 42
- FWCI
- 26.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.